A Post-authorization Study to Describe the Safety and Efficacy of Emapalumab for the Treatment of pHLH in Treatment Experienced Chinese Patients

Primary Hemophagocytic Lymphohistiocytosis Clinical Trial

Official title:
An Open Label, Single Arm, Multi-Centre, Post-authorization Study to Describe the Safety and Efficacy of Emapalumab for the Treatment of Primary Hemophagocytic Lymphohistiocytosis in Treatment Experienced Chinese Patients

Status Active, not recruiting

Clinical Trial Summary

The goal of this post-authorization study is to describe safety and efficacy of emapalumab in treatment experienced Chinese patients with pHLH.

Clinical Trial Description

This is an open-label, multi center, single arm, post-authorization study aiming to describe safety and efficacy of emapalumab in treatment experienced Chinese patients with confirmed or suspected primary hemophagocytic lymphohistiocytosis (pHLH). The main objectives of the study are to collect safety and efficacy data on emapalumab in treatment experienced Chinese pHLH patients ;

Study Design

Related Conditions & MeSH terms

Lymphohistiocytosis, Hemophagocytic
Primary Hemophagocytic Lymphohistiocytosis

Clinical Trial Details

NCT number	NCT05744063
Study type	Interventional
Source	Swedish Orphan Biovitrum
Contact
Status	Active, not recruiting
Phase	Phase 4
Start date	February 3, 2023
Completion date	July 2025

View Details

See also
	Status	Clinical Trial	Phase
	Active, not recruiting	`NCT03827343` - Retrospective Study of Immunotherapy Related Toxicities and Factors Impacting Outcomes in Children and Adults With Cancer
	Completed	`NCT03312751` - Study to Assess the Efficacy and Safety of Emapalumab in Primary Haemophagocytic Lymphohistiocytosis	Phase 3